Juan Antonio Alarcon, MD
Urology · Montebello
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 49 years
- Graduated 1977
Offices
1 location
Hospitals listed: Adventist Health White Memorial · Monterey Park Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Alarcon’s office at (626) 284-9278 to ask if they take your plan before you enroll.
California Medical Board record
Licence A40197 · Current
Licensed to practise in California · since 1983 · expires 2028-08-31 · Autonomous University of Guadalajara Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- LB Surgery Center LLCOffice-Based Surgery Center · Long Beach, CA6% owner since 2012 · accredited by AAAASFCanceled2 inspections, 1 with deficiencies · last 2017-10-25: Requirements Met
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Urology - Urology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health White MemorialLos Angeles, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 2 of 5 · 64% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.165, Oct 2024 – Sep 2025
- Monterey Park HospitalMonterey Park, CAAcute Care Hospital · Proprietary · No emergency departmentPatients rate it 2 of 5 · 58% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health White Memorial
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 5 the same, 1 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.165 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.29) · 473 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.95 (0.58 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.08 (101.25 to 214.92) · 35 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.2 · 28 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.5 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.9 · 163 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.9 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.8 · 157 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.1 · 2,433 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 3,215 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 3,320 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.84 (0.46 to 5.23) · 632 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.51 (0 to 3.16) · 172 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.98 (0.38 to 3.58) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.96 (2.37 to 19.55) · 186 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.48 to 9.73) · 166 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 77 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.45 (0 to 1.22) · 2,746 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 207 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.403 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.034 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.673 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.803 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.392 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 257 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 517 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -34.6 · 74 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -21.5 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4 · 208 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 497 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 218 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 97 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9 to 16.4) · 199 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 51 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,008 patients answered, 10% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 79% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Monterey Park Hospital
Behind the star rating — Deaths: 0 better, 3 the same, 0 worse of 3 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 2 the same, 2 worse of 4 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 222 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.46 to 1.37) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 77 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 16.5 · 41 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.7 · 548 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 976 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 1,025 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.31 (0.74 to 5.88) · 150 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.67 (0 to 3.41) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.56 (0.86 to 4.26) · 149 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.19 (0 to 19.27) · 29 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.22 (0.88 to 9.56) · 30 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.28) · 37 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.4 (0 to 1.47) · 845 cases | No different | Jul 2022 – Jun 2024 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 37 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.4 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 19.3 · 37 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 30 · 86 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 30 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.2 to 16.9) · 108 cases | No different | Jan 2022 – Dec 2024 |
What patients said (326 patients answered, 13% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 68% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 76% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 66% |
| Doctors "always" treated them with courtesy and respect | 73% |
| Patients who gave a rating of "9" or "10" (high) | 59% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 66% |
| Nurses "always" listened carefully | 67% |
| Nurses "always" treated them with courtesy and respect | 77% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 58% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$171,494
Medicare paid this office $171,494 for 530 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 411 | $56,127 | $73 |
| Diagnostic exam of bladder and urethra using an endoscope | 74 | $16,586 | $218 |
| New patient visit (30+ min) | 111 | $9,715 | $88 |
| Insertion of lower leg neurostimulator electrode | 12 | $9,502 | $106 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 22 | $7,998 | $364 |
See all 20 services
| Short return visit (20+ min) | 411 | $56,127 | $73 |
| Diagnostic exam of bladder and urethra using an endoscope | 74 | $16,586 | $218 |
| New patient visit (30+ min) | 111 | $9,715 | $88 |
| Insertion of lower leg neurostimulator electrode | 12 | $9,502 | $106 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 22 | $7,998 | $364 |
| Return visit (30+ min) | 63 | $7,907 | $110 |
| Insertion of device into abdomen with pressure and urine flow rate study | 33 | $6,146 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $6,085 | $105 |
| Simple change of bladder tube | 13 | $4,999 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $4,973 | $70 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 11 | $3,809 | $346 |
| New patient visit (45+ min) | 21 | $2,833 | $135 |
| Ultrasound measurement of bladder capacity after voiding | 210 | $2,610 | $10 |
| Ultrasound scan of pelvic region through rectum | 15 | $2,048 | $137 |
| Electronic assessment of bladder emptying | 121 | $1,304 | $10 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 33 | $1,000 | $30 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $485 | $32 |
| Automated urinalysis test | 107 | $361 | $2 |
| Injection of drug or substance under skin or into muscle | 13 | $218 | $11 |
| Injection, ceftriaxone sodium, per 250 mg | 12 | $4 | None |
Procedures Medicare counted
| Prostate resection | 15 | More than 70% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Ultrasound measurement of bladder capacity after voiding | 451 | 287 | 291 | 277 | 256 | 255 |
| Insertion of lower leg neurostimulator electrode | 402 | 281 | 235 | 156 | 68 | 90 |
| Electronic assessment of bladder emptying | 307 | 162 | 150 | 152 | 146 | 130 |
| Diagnostic exam of bladder and urethra using an endoscope | 179 | 130 | 116 | 115 | 89 | 76 |
| Insertion of device into abdomen with pressure and urine flow rate study | 103 | 58 | 58 | 60 | 30 | 33 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 103 | 58 | 58 | 60 | 30 | 33 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
530 Original Medicare patients in 2024. Average age 75 · Under 65 10% · 85 and older 17% · Women 22% · Also on Medicaid 78% · Health risk score 1.94. Sicker patients than 9 in 10 peers; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Diabetes 63% · Chronic kidney disease 42% · Coronary heart disease 35% · Depression 25% · Heart failure 23% · Cancer 20% · Atrial fibrillation 18% · COPD 17% · Dementia 16% · Stroke 11%.
The office billed $454,498, Medicare allowed $231,069 and paid $171,494; for 2,196 services of 63 kinds; $25 of it was for drugs given in the office and $171,469 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 530 | 2,196 | 75 | 1.94 | $454,498 | $171,494 |
| 2023 | 560 | 2,475 | 75 | 2.00 | $463,747 | $166,373 |
| 2022 | 589 | 3,255 | 74 | 2.00 | $581,534 | $212,532 |
| 2021 | 571 | 3,738 | 74 | 1.85 | $653,801 | $239,545 |
| 2020 | 588 | 3,355 | 74 | 2.02 | $724,564 | $260,437 |
| 2019 | 702 | 4,606 | 74 | 2.10 | $1,098,746 | $395,419 |
| 2018 | 723 | 5,552 | 74 | 1.87 | $1,011,821 | $348,982 |
| 2017 | 742 | 6,535 | 74 | 1.90 | $1,330,706 | $394,821 |
| 2016 | 820 | 8,846 | 74 | 1.80 | $1,949,711 | $699,654 |
| 2015 | 829 | 9,812 | 74 | 1.87 | $2,099,617 | $704,747 |
| 2014 | 930 | 9,805 | 74 | 1.65 | $2,153,325 | $696,158 |
| 2013 | 987 | 10,005 | 74 | 1.78 | $2,233,459 | $681,994 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 18 services
| Short return visit (20+ min) | 422 | $52,353 | $67 |
| Diagnostic exam of bladder and urethra using an endoscope | 87 | $17,964 | $202 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $9,182 | $102 |
| New patient visit (30+ min) | 103 | $8,963 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $7,055 | $68 |
| Insertion of lower leg neurostimulator electrode | 12 | $6,099 | $90 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 16 | $5,579 | $349 |
| Insertion of device into abdomen with pressure and urine flow rate study | 30 | $5,465 | $182 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 14 | $4,279 | $306 |
| Return visit (30+ min) | 34 | $3,775 | $99 |
| Ultrasound measurement of bladder capacity after voiding | 208 | $2,358 | $9 |
| New patient visit (45+ min) | 14 | $1,674 | $120 |
| Electronic assessment of bladder emptying | 133 | $1,327 | $9 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 30 | $865 | $29 |
| Automated urinalysis test | 132 | $436 | $2 |
| Injection of drug or substance under skin or into muscle | 14 | $345 | $13 |
| Injection, garamycin, gentamicin, up to 80 mg | 11 | $29 | None |
| Injection, ceftriaxone sodium, per 250 mg | 12 | $6 | None |
2022: 19 services
| Short return visit (20+ min) | 430 | $53,003 | $68 |
| Diagnostic exam of bladder and urethra using an endoscope | 111 | $22,779 | $198 |
| Insertion of lower leg neurostimulator electrode | 22 | $16,236 | $104 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 33 | $11,960 | $362 |
| Insertion of device into abdomen with pressure and urine flow rate study | 60 | $11,234 | $187 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 27 | $9,419 | $349 |
| Return visit (30+ min) | 77 | $9,164 | $110 |
| New patient visit (30+ min) | 98 | $8,293 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $7,272 | $86 |
| New patient visit (45+ min) | 57 | $7,170 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $3,803 | $59 |
| Ultrasound measurement of bladder capacity after voiding | 228 | $2,576 | $9 |
| Ultrasound scan of pelvic region through rectum | 15 | $1,994 | $133 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 60 | $1,724 | $29 |
| Electronic assessment of bladder emptying | 140 | $1,326 | $9 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 21 | $880 | $21 |
| Automated urinalysis test | 208 | $608 | $2 |
| Injection of drug or substance under skin or into muscle | 19 | $221 | $11 |
| Injection, ceftriaxone sodium, per 250 mg | 16 | $6 | None |
2021: 22 services
| Short return visit (20+ min) | 427 | $61,058 | $71 |
| Insertion of lower leg neurostimulator electrode | 26 | $26,409 | $112 |
| Diagnostic exam of bladder and urethra using an endoscope | 108 | $18,387 | $159 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 36 | $13,234 | $368 |
| Insertion of device into abdomen with pressure and urine flow rate study | 58 | $9,889 | $171 |
| New patient visit (30+ min) | 114 | $9,333 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $7,936 | $88 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 22 | $7,255 | $330 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $4,681 | $62 |
| Biopsy of prostate gland | 16 | $3,402 | $213 |
| Return visit (30+ min) | 27 | $3,363 | $112 |
| New patient visit (45+ min) | 25 | $3,115 | $125 |
| Ultrasound scan of pelvic region through rectum | 25 | $2,957 | $118 |
| Ultrasound measurement of bladder capacity after voiding | 226 | $2,639 | $9 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 58 | $1,659 | $29 |
| Electronic assessment of bladder emptying | 143 | $1,348 | $9 |
| Automated urinalysis test | 306 | $947 | $2 |
| Ultrasonic guidance for needle placement | 16 | $847 | $53 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $590 | $18 |
| Injection of drug or substance under skin or into muscle | 22 | $295 | $11 |
| Injection, garamycin, gentamicin, up to 80 mg | 17 | $23 | None |
| Injection, ceftriaxone sodium, per 250 mg | 17 | $7 | None |
2020: 24 services
| Short return visit (20+ min) | 353 | $33,858 | $57 |
| Insertion of lower leg neurostimulator electrode | 34 | $31,466 | $112 |
| Return visit (30+ min) | 214 | $23,458 | $85 |
| Diagnostic exam of bladder and urethra using an endoscope | 123 | $21,112 | $162 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 29 | $9,589 | $331 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 29 | $9,117 | $314 |
| Insertion of device into abdomen with pressure and urine flow rate study | 58 | $8,888 | $153 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 62 | $7,605 | $91 |
| New patient visit (30+ min) | 87 | $7,166 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $6,868 | $63 |
| New patient visit (45+ min) | 49 | $5,461 | $111 |
| Ultrasound scan of pelvic region through rectum | 30 | $3,987 | $133 |
| Biopsy of prostate gland | 15 | $3,451 | $230 |
| Ultrasound measurement of bladder capacity after voiding | 219 | $2,580 | $9 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 58 | $1,784 | $31 |
| Electronic assessment of bladder emptying | 143 | $1,452 | $9 |
| Automated urinalysis test | 289 | $915 | $2 |
| Ultrasonic guidance for needle placement | 15 | $788 | $53 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $513 | $20 |
| Short return visit | 11 | $483 | $40 |
| Injection of drug or substance under skin or into muscle | 21 | $324 | $12 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 11 | $132 | $12 |
| Injection, garamycin, gentamicin, up to 80 mg | 20 | $31 | None |
| Injection, ceftriaxone sodium, per 250 mg | 16 | $7 | None |
2019: 24 services
| Short return visit (20+ min) | 475 | $49,652 | $55 |
| Insertion of lower leg neurostimulator electrode | 48 | $45,591 | $113 |
| Diagnostic exam of bladder and urethra using an endoscope | 166 | $26,894 | $150 |
| Return visit (30+ min) | 254 | $26,380 | $86 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 53 | $16,110 | $293 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 49 | $15,832 | $323 |
| Insertion of device into abdomen with pressure and urine flow rate study | 102 | $13,127 | $127 |
| New patient visit (30+ min) | 109 | $9,145 | $84 |
| New patient visit (45+ min) | 73 | $7,670 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 56 | $7,029 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $5,640 | $88 |
| Ultrasound measurement of bladder capacity after voiding | 324 | $4,854 | $11 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 102 | $3,099 | $30 |
| Ultrasound scan of pelvic region through rectum | 24 | $2,830 | $113 |
| Electronic assessment of bladder emptying | 257 | $2,734 | $9 |
| Biopsy of prostate gland | 12 | $2,558 | $213 |
| Complicated insertion of bladder tube | 14 | $1,771 | $118 |
| Automated urinalysis test | 295 | $928 | $2 |
| Short return visit | 20 | $814 | $37 |
| Injection of drug or substance under skin or into muscle | 21 | $625 | $14 |
| Ultrasonic guidance for needle placement | 12 | $606 | $51 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $421 | $28 |
| Injection, garamycin, gentamicin, up to 80 mg | 13 | $23 | None |
| Injection, ceftriaxone sodium, per 250 mg | 18 | $10 | None |
2018: 31 services
| Short return visit (20+ min) | 520 | $56,437 | $55 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 15 | $41,584 | $904 |
| Insertion of lower leg neurostimulator electrode | 41 | $34,796 | $112 |
| Return visit (30+ min) | 243 | $24,852 | $83 |
| Diagnostic exam of bladder and urethra using an endoscope | 165 | $22,121 | $127 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 15 | $18,637 | $1,165 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 49 | $15,414 | $308 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 47 | $13,067 | $278 |
| New patient visit (45+ min) | 97 | $11,552 | $119 |
| Insertion of multicomponent inflatable penile implant | 16 | $11,088 | $693 |
| Insertion of device into abdomen with pressure and urine flow rate study | 96 | $9,852 | $102 |
| New patient visit (30+ min) | 75 | $6,315 | $84 |
| Ultrasound measurement of bladder capacity after voiding | 312 | $5,987 | $14 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $3,406 | $62 |
| Biopsy of prostate gland | 15 | $3,305 | $220 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 96 | $3,010 | $31 |
| Ultrasound scan of pelvic region through rectum | 34 | $2,971 | $87 |
| Electronic assessment of bladder emptying | 233 | $2,787 | $10 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $2,749 | $86 |
| Psa (prostate specific antigen) measurement, total | 106 | $2,360 | $22 |
| Complicated insertion of bladder tube | 17 | $1,768 | $104 |
| Automated urinalysis test | 426 | $1,722 | $3 |
| Insertion of needle into vein for collection of blood sample | 272 | $994 | $3 |
| Testosterone (hormone) level, total | 27 | $968 | $30 |
| Long return visit (40+ min) | 12 | $895 | $75 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 24 | $854 | $27 |
| Ultrasonic guidance for needle placement | 15 | $802 | $53 |
| Injection of drug or substance under skin or into muscle | 28 | $796 | $17 |
| Short return visit | 21 | $694 | $32 |
| Injection, garamycin, gentamicin, up to 80 mg | 21 | $30 | None |
| Injection, ceftriaxone sodium, per 250 mg | 20 | $10 | None |
2017: 36 services
| Short return visit (20+ min) | 537 | $64,651 | $54 |
| Insertion of lower leg neurostimulator electrode | 54 | $55,892 | $106 |
| Return visit (30+ min) | 291 | $29,757 | $75 |
| Diagnostic exam of bladder and urethra using an endoscope | 164 | $20,805 | $113 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 65 | $18,671 | $267 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 40 | $11,652 | $291 |
| New patient visit (45+ min) | 104 | $11,549 | $111 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $11,389 | None |
| Insertion of device into abdomen with pressure and urine flow rate study | 105 | $10,587 | $96 |
| Unclassified drugs | 15 | $10,504 | None |
| Psa (prostate specific antigen) measurement, total | 312 | $9,941 | $25 |
| Insertion of multicomponent inflatable penile implant | 14 | $9,363 | $669 |
| Ultrasound measurement of bladder capacity after voiding | 344 | $8,119 | $16 |
| New patient visit (30+ min) | 69 | $4,702 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $4,536 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $4,175 | $85 |
| Testosterone (hormone) level, total | 79 | $3,886 | $35 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 105 | $3,338 | $30 |
| Biopsy of prostate gland | 18 | $3,313 | $184 |
| Complicated insertion of bladder tube | 30 | $3,311 | $103 |
| Ultrasound scan of pelvic region through rectum | 39 | $3,129 | $80 |
| Simple bladder irrigation and/or instillation | 13 | $3,078 | $58 |
| Electronic assessment of bladder emptying | 257 | $3,047 | $10 |
| Short return visit | 92 | $2,810 | $25 |
| Automated urinalysis test | 479 | $2,537 | $3 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 13 | $2,436 | $187 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 13 | $1,851 | $50 |
| Long return visit (40+ min) | 17 | $1,566 | $87 |
| Placement of hormone pellet under skin | 14 | $1,285 | $64 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 30 | $1,101 | $26 |
| Ultrasonic guidance for needle placement | 18 | $874 | $49 |
| Insertion of needle into vein for collection of blood sample | 234 | $870 | $3 |
| Injection of drug or substance under skin or into muscle | 23 | $611 | $19 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $242 | $12 |
| Injection, garamycin, gentamicin, up to 80 mg | 16 | $21 | None |
| Injection, ceftriaxone sodium, per 250 mg | 26 | $17 | None |
2016: 42 services
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 41 | $91,367 | $870 |
| Insertion of lower leg neurostimulator electrode | 79 | $84,548 | $112 |
| Short return visit (20+ min) | 534 | $60,326 | $55 |
| Return visit (30+ min) | 454 | $55,320 | $80 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 41 | $46,203 | $1,127 |
| Diagnostic exam of bladder and urethra using an endoscope | 234 | $41,945 | $163 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 58 | $17,872 | $303 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 57 | $16,370 | $268 |
| Unclassified drugs | 29 | $15,921 | None |
| Insertion of multicomponent inflatable penile implant | 19 | $13,284 | $699 |
| Insertion of device into abdomen with pressure and urine flow rate study | 115 | $11,992 | $100 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 17 | $11,865 | $698 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 117 | $11,822 | $92 |
| New patient visit (45+ min) | 90 | $11,760 | $131 |
| Psa (prostate specific antigen) measurement, total | 365 | $11,592 | $25 |
| Ultrasound measurement of bladder capacity after voiding | 419 | $11,344 | $17 |
| Short return visit | 202 | $9,485 | $35 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 14 | $8,303 | $593 |
| Simple bladder irrigation and/or instillation | 17 | $7,281 | $69 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 13 | $6,742 | $157 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $6,657 | $61 |
| New patient visit (30+ min) | 85 | $6,531 | $77 |
| Testosterone (hormone) level, total | 133 | $6,308 | $34 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $5,638 | $88 |
| Ultrasound scan of pelvic region through rectum | 62 | $5,477 | $83 |
| Complete ultrasound scan behind abdominal cavity | 59 | $5,253 | $86 |
| Biopsy of prostate gland | 23 | $4,557 | $190 |
| Electronic assessment of bladder emptying | 325 | $4,022 | $10 |
| Dilation of urethra using an endoscope | 15 | $3,849 | $226 |
| Long return visit (40+ min) | 29 | $3,204 | $110 |
| Automated urinalysis test | 518 | $2,811 | $3 |
| Placement of hormone pellet under skin | 29 | $2,799 | $82 |
| Injection of drug or substance under skin or into muscle | 48 | $1,554 | $22 |
| Insertion of needle into vein for collection of blood sample | 363 | $1,438 | $3 |
| Insertion of stent in ureter using an endoscope | 11 | $1,426 | $110 |
| Ultrasonic guidance for needle placement | 22 | $1,232 | $54 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 46 | $1,105 | $16 |
| Insertion of temporary bladder tube | 11 | $679 | $45 |
| Creatinine level to test for kidney function or muscle injury | 87 | $636 | $7 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 20 | $608 | $28 |
| Injection, garamycin, gentamicin, up to 80 mg | 28 | $56 | None |
| Injection, ceftriaxone sodium, per 250 mg | 26 | $44 | None |
2015: 50 services
| Return visit (30+ min) | 544 | $76,316 | $83 |
| Short return visit (20+ min) | 520 | $64,124 | $58 |
| Diagnostic exam of bladder and urethra using an endoscope | 238 | $41,775 | $164 |
| Insertion of lower leg neurostimulator electrode | 50 | $38,984 | $106 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 18 | $36,400 | $867 |
| Cell examination of urine, manual | 37 | $23,137 | $551 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 20 | $21,741 | None |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 71 | $21,093 | $278 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 18 | $20,181 | $1,121 |
| Unclassified drugs | 29 | $19,494 | None |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 60 | $18,901 | $300 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 134 | $15,007 | $96 |
| Insertion of device into abdomen with pressure and urine flow rate study | 131 | $13,904 | $100 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 19 | $13,379 | $704 |
| Psa (prostate specific antigen) measurement, total | 395 | $12,978 | $24 |
| Ultrasound measurement of bladder capacity after voiding | 437 | $12,018 | $16 |
| Insertion of multicomponent inflatable penile implant | 17 | $11,868 | $698 |
| Complete ultrasound scan behind abdominal cavity | 113 | $11,689 | $97 |
| New patient visit (30+ min) | 131 | $10,270 | $78 |
| Testosterone (hormone) level, total | 198 | $8,986 | $34 |
| New patient visit (45+ min) | 64 | $8,212 | $128 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 16 | $8,136 | $479 |
| Short return visit | 177 | $7,239 | $30 |
| Pathology examination of tissue using a microscope, intermediate complexity | 24 | $7,033 | $42 |
| Simple bladder irrigation and/or instillation | 17 | $6,008 | $68 |
| Creation of sling around urethra in female to control leakage | 12 | $5,851 | $488 |
| Shock wave crushing of kidney stones | 11 | $5,414 | $492 |
| Electronic assessment of bladder emptying | 354 | $5,275 | $11 |
| Study of rectum sensitivity and function | 12 | $4,539 | $197 |
| Biopsy of prostate gland | 23 | $4,475 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $4,365 | $58 |
| Ultrasound scan of pelvic region through rectum | 42 | $3,600 | $84 |
| Placement of hormone pellet under skin | 28 | $3,225 | $79 |
| Long return visit (40+ min) | 23 | $2,908 | $116 |
| Automated urinalysis test | 559 | $2,799 | $3 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 67 | $2,274 | $17 |
| Insertion of needle into vein for collection of blood sample | 435 | $1,888 | $3 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,861 | $116 |
| Injection procedure to cause erection | 15 | $1,528 | $76 |
| Simple insertion of temporary bladder tube | 12 | $1,379 | $60 |
| Ultrasonic guidance for needle placement | 23 | $1,271 | $53 |
| Application of electrical stimulation with therapist present, each 15 minutes | 13 | $993 | $14 |
| Cell examination of specimen, selective cellular enhancement technique | 15 | $970 | $57 |
| Injection of drug or substance under skin or into muscle | 36 | $902 | $22 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $809 | $74 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 25 | $794 | $27 |
| Creatinine level to test for kidney function or muscle injury | 63 | $462 | $7 |
| Manual urinalysis test with examination using microscope, non-automated | 14 | $63 | $4 |
| Injection, garamycin, gentamicin, up to 80 mg | 28 | $49 | None |
| Injection, ceftriaxone sodium, per 250 mg | 11 | $26 | None |
2014: 51 services
| Return visit (30+ min) | 505 | $62,278 | $80 |
| Short return visit (20+ min) | 602 | $62,208 | $55 |
| Diagnostic exam of bladder and urethra using an endoscope | 250 | $41,915 | $158 |
| Cell examination of urine, manual | 58 | $35,101 | $557 |
| Destruction of prostate tissue using microwave induced heat | 13 | $23,678 | $1,821 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 69 | $20,375 | $295 |
| Insertion of lower leg neurostimulator electrode | 30 | $19,921 | $103 |
| Unclassified drugs | 28 | $17,938 | None |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 62 | $17,601 | $267 |
| Complete ultrasound scan behind abdominal cavity | 146 | $16,871 | $60 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 133 | $16,340 | $100 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 22 | $15,544 | $707 |
| Psa (prostate specific antigen) measurement, total | 485 | $14,732 | $24 |
| New patient visit (30+ min) | 180 | $13,340 | $74 |
| Insertion of device into abdomen with pressure and urine flow rate study | 131 | $13,215 | $98 |
| Insertion of multicomponent inflatable penile implant | 19 | $12,764 | $672 |
| Short return visit | 228 | $11,912 | $33 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 27 | $11,439 | $424 |
| Ultrasound measurement of bladder capacity after voiding | 470 | $10,883 | $16 |
| Testosterone (hormone) level, total | 202 | $8,701 | $34 |
| Simple bladder irrigation and/or instillation | 19 | $8,467 | $63 |
| Pathology examination of tissue using a microscope, intermediate complexity | 28 | $8,069 | $33 |
| Study of rectum sensitivity and function | 20 | $6,821 | $195 |
| New patient visit (45+ min) | 56 | $6,592 | $118 |
| Creation of sling around urethra in female to control leakage | 12 | $6,393 | $533 |
| Biopsy of prostate gland | 27 | $4,896 | $181 |
| Ultrasound scan of pelvic region through rectum | 58 | $4,731 | $80 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 22 | $4,669 | $97 |
| Dilation of urethra using an endoscope | 17 | $4,220 | $211 |
| Electronic assessment of bladder emptying | 326 | $3,900 | $10 |
| Automated urinalysis test | 699 | $3,811 | $3 |
| Cell examination of specimen, selective cellular enhancement technique | 65 | $3,293 | $47 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $3,136 | $59 |
| Placement of hormone pellet under skin | 25 | $2,941 | $86 |
| Injection procedure to cause erection | 28 | $2,716 | $73 |
| Insertion of needle into vein for collection of blood sample | 511 | $2,020 | $3 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 40 | $1,822 | $17 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 14 | $1,778 | $89 |
| Ultrasonic guidance for needle placement | 27 | $1,746 | $65 |
| Long return visit (40+ min) | 13 | $1,481 | $114 |
| Creatinine level to test for kidney function or muscle injury | 178 | $1,405 | $7 |
| Application of electrical stimulation with therapist present, each 15 minutes | 21 | $1,352 | $15 |
| Simple insertion of temporary bladder tube | 13 | $1,289 | $59 |
| Injection of drug or substance under skin or into muscle | 48 | $1,216 | $21 |
| Ultrasound scan of scrotum | 17 | $1,195 | $31 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $953 | $79 |
| Test or measurement for functional capacity, each 15 minutes | 11 | $950 | $29 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $508 | $25 |
| Injection, ceftriaxone sodium, per 250 mg | 19 | $54 | None |
| Injection, garamycin, gentamicin, up to 80 mg | 27 | $45 | None |
| Injection, aminophyllin, up to 250 mg | 13 | $20 | None |
2013: 45 services
| Return visit (30+ min) | 544 | $64,143 | $78 |
| Cell examination of urine, manual | 83 | $48,804 | $561 |
| Short return visit (20+ min) | 559 | $48,109 | $55 |
| Diagnostic exam of bladder and urethra using an endoscope | 271 | $47,649 | $158 |
| Pathology examination of tissue using a microscope, intermediate complexity | 59 | $41,797 | $60 |
| Destruction of prostate tissue using microwave induced heat | 17 | $31,773 | $1,869 |
| Insertion of lower leg neurostimulator electrode | 29 | $27,221 | $108 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 76 | $22,243 | $275 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 69 | $21,022 | $296 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 140 | $15,617 | $96 |
| Insertion of device into abdomen with pressure and urine flow rate study | 139 | $14,492 | $100 |
| Simple bladder irrigation and/or instillation | 36 | $13,987 | $66 |
| Insertion of multicomponent inflatable penile implant | 21 | $13,063 | $594 |
| New patient visit (30+ min) | 154 | $12,637 | $82 |
| Complete ultrasound scan behind abdominal cavity | 101 | $12,606 | $81 |
| Ultrasound measurement of bladder capacity after voiding | 494 | $11,707 | $16 |
| Short return visit | 231 | $11,204 | $36 |
| Ultrasonic guidance for needle placement | 59 | $11,034 | $184 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 16 | $10,964 | $685 |
| Biopsy of prostate gland | 59 | $10,792 | $183 |
| Psa (prostate specific antigen) measurement, total | 370 | $10,610 | $25 |
| Cell examination of specimen, selective cellular enhancement technique | 90 | $9,037 | $94 |
| New patient visit (45+ min) | 67 | $7,199 | $107 |
| Ultrasound scan of pelvic region through rectum | 101 | $6,915 | $61 |
| Dilation of urethra using an endoscope | 28 | $6,189 | $213 |
| Complete removal of remaining or regrown prostate tissue with control of bleeding using an endoscope | 15 | $5,304 | $331 |
| Study of rectum sensitivity and function | 13 | $4,995 | $200 |
| Testosterone (hormone) level, total | 116 | $4,174 | $35 |
| Automated urinalysis test | 648 | $3,238 | $3 |
| Electronic assessment of bladder emptying | 289 | $2,901 | $9 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,689 | $58 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 16 | $2,366 | $91 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 24 | $2,294 | $79 |
| New patient visit (15+ min) | 39 | $2,239 | $57 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 51 | $2,099 | $17 |
| Simple insertion of temporary bladder tube | 22 | $1,887 | $57 |
| Injection procedure to cause erection | 19 | $1,743 | $76 |
| Insertion of needle into vein for collection of blood sample | 402 | $1,415 | $3 |
| Application of electrical stimulation with therapist present, each 15 minutes | 13 | $1,177 | $14 |
| Injection of drug or substance under skin or into muscle | 39 | $1,046 | $23 |
| Creatinine level to test for kidney function or muscle injury | 77 | $591 | $7 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $404 | $27 |
| Manual urinalysis test with examination using microscope, automated | 17 | $77 | $4 |
| Injection, ceftriaxone sodium, per 250 mg | 26 | $69 | None |
| Injection, garamycin, gentamicin, up to 80 mg | 17 | $29 | None |
Medicaid work
$6,910 in 2024
Medicaid paid $6,910 for 563 billed services this clinician did in 2024, up to 49 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 409 | $5,760 |
| New patient visit (30+ min) | 40 | $898 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 58 | $210 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 12 | $36 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 44 | $7 |
| 2024 | 563 | 5 | 49 | $6,910 |
| 2023 | 1,343 | 10 | 64 | $18,143 |
| 2022 | 1,039 | 7 | 61 | $10,663 |
| 2021 | 877 | 6 | 49 | $8,068 |
| 2020 | 779 | 5 | 43 | $2,512 |
| 2019 | 1,050 | 6 | 52 | $3,347 |
| 2018 | 969 | 7 | 63 | $7,005 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 669 | $12,140 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 68 | $1,970 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 32 | $1,401 |
| New patient visit (30+ min) | 103 | $1,069 |
| CYSTOURETHROSCOPY | 16 | $598 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 193 | $507 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 89 | $159 |
| INTRAABDOMINAL PRESSURE TEST | 12 | $149 |
| ANAL/URINARY MUSCLE STUDY | 12 | $108 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 149 | $43 |
2022
| Short return visit (20+ min) | 552 | $7,496 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 34 | $967 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 14 | $860 |
| New patient visit (30+ min) | 103 | $701 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 171 | $386 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 58 | $207 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 107 | $46 |
2021
| Short return visit (20+ min) | 444 | $6,092 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 13 | $1,188 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 19 | $404 |
| New patient visit (30+ min) | 79 | $200 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 66 | $152 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 256 | $32 |
2020
| Short return visit (20+ min) | 366 | $1,877 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 77 | $378 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 237 | $127 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 39 | $102 |
| New patient visit (30+ min) | 60 | $29 |
2019
| Short return visit (20+ min) | 478 | $979 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 24 | $876 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 165 | $746 |
| New patient visit (30+ min) | 90 | $359 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 130 | $272 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 163 | $115 |
2018
| Short return visit (20+ min) | 472 | $5,029 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 137 | $1,113 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 24 | $454 |
| Return visit (30+ min) | 16 | $163 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 39 | $119 |
| New patient visit (30+ min) | 47 | $99 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 234 | $30 |
Drugs they prescribed that Part D paid
$1,900,115
Pharmacies billed $1,900,115 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
4,001 generic and fewer than 11 brand-name prescriptions · $1,900,115 in drug cost · 843 antibiotic prescriptions to 518 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 45 | $721,538 | $16,034 |
| Lupron Depot | 61 | $703,858 | $11,539 |
| Gemtesa | 289 | $240,925 | $834 |
| Myrbetriq | 144 | $112,674 | $782 |
| Tamsulosin | 1,491 | $27,553 | $18 |
See all 27 drugs
| Xtandi | 45 | $721,538 | $16,034 |
| Lupron Depot | 61 | $703,858 | $11,539 |
| Gemtesa | 289 | $240,925 | $834 |
| Myrbetriq | 144 | $112,674 | $782 |
| Tamsulosin | 1,491 | $27,553 | $18 |
| Finasteride | 933 | $12,517 | $13 |
| Silodosin | 12 | $2,429 | $202 |
| Dutasteride | 52 | $2,204 | $42 |
| Oxybutynin Chloride | 156 | $1,757 | $11 |
| Bicalutamide | 41 | $1,645 | $40 |
| Oxybutynin Chloride Er | 70 | $1,535 | $22 |
| Ciprofloxacin | 575 | $1,456 | $3 |
| Solifenacin | 12 | $1,352 | $113 |
| Estradiol | 25 | $1,208 | $48 |
| Alfuzosin Hcl Er | 30 | $663 | $22 |
| Nitrofurantoin Mono-Macro | 50 | $548 | $11 |
| Terazosin | 26 | $535 | $21 |
| Doxazosin Mesylate | 20 | $469 | $23 |
| Amoxicillin-Clavulanate Potass | 144 | $448 | $3 |
| Trospium Chloride | 15 | $442 | $29 |
| Ibuprofen | 124 | $316 | $3 |
| Sildenafil Citrate | 52 | $268 | $5 |
| Tolterodine Tartrate Er | 11 | $254 | $23 |
| Bethanechol Chloride | 16 | $215 | $13 |
| Doxycycline Hyclate | 37 | $145 | $4 |
| Sulfamethoxazole-Trimethoprim | 24 | $90 | $4 |
| Naproxen | 14 | $81 | $6 |
Year by year
| 2024 | 4,565 | 1,109 | None | None | $1,900,115 |
| 2023 | 4,290 | 1,061 | 0% (11) | 11% | $1,678,273 |
| 2022 | 4,394 | 1,108 | 1% (30) | 13% | $1,928,223 |
| 2021 | 4,173 | 980 | 2% (66) | None | $1,313,584 |
| 2020 | 4,653 | 973 | 2% (72) | None | $856,199 |
| 2019 | 4,858 | 973 | 1% (35) | None | $974,996 |
| 2018 | 3,812 | 795 | 2% (82) | None | $830,350 |
| 2017 | 3,183 | 620 | 3% (92) | None | $684,727 |
| 2016 | 4,335 | 736 | 3% (130) | None | $538,871 |
| 2015 | 4,683 | 719 | 4% (172) | 22% | $520,912 |
| 2014 | 5,084 | 787 | 3% (149) | 28% | $618,100 |
| 2013 | 5,009 | 813 | 3% (128) | 30% | $512,478 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 27 drugs
| Xtandi | 50 | $752,795 | $15,056 |
| Lupron Depot | 36 | $443,193 | $12,311 |
| Myrbetriq | 227 | $200,163 | $882 |
| Gemtesa | 99 | $93,375 | $943 |
| Tamsulosin | 1,439 | $52,025 | $36 |
| Finasteride | 823 | $22,380 | $27 |
| Elmiron | 11 | $11,320 | $1,029 |
| Oxybutynin Chloride Er | 215 | $8,897 | $41 |
| Bicalutamide | 42 | $2,664 | $63 |
| Oxybutynin Chloride | 103 | $2,458 | $24 |
| Dutasteride | 28 | $2,351 | $84 |
| Dutasteride-Tamsulosin | 12 | $1,987 | $166 |
| Ciprofloxacin | 415 | $1,741 | $4 |
| Cefaclor | 18 | $1,580 | $88 |
| Trospium Chloride | 15 | $1,417 | $94 |
| Amoxicillin-Clavulanate Potass | 204 | $1,390 | $7 |
| Bethanechol Chloride | 16 | $1,353 | $85 |
| Alfuzosin Hcl Er | 35 | $1,290 | $37 |
| Sildenafil Citrate | 82 | $771 | $9 |
| Terazosin | 24 | $650 | $27 |
| Doxycycline Hyclate | 48 | $564 | $12 |
| Nitrofurantoin Mono-Macro | 22 | $561 | $26 |
| Doxazosin Mesylate | 14 | $446 | $32 |
| Ibuprofen | 86 | $304 | $4 |
| Sulfamethoxazole-Trimethoprim | 30 | $184 | $6 |
| Levofloxacin | 18 | $101 | $6 |
| Naproxen | 12 | $30 | $3 |
2022: 34 drugs
| Xtandi | 65 | $910,995 | $14,015 |
| Lupron Depot | 43 | $485,961 | $11,301 |
| Myrbetriq | 315 | $241,920 | $768 |
| Elmiron | 50 | $57,715 | $1,154 |
| Tamsulosin | 1,303 | $35,425 | $27 |
| Trelstar | 12 | $31,486 | $2,624 |
| Gemtesa | 17 | $19,136 | $1,126 |
| Toviaz | 18 | $17,812 | $990 |
| Finasteride | 698 | $15,042 | $22 |
| Oxybutynin Chloride Er | 216 | $9,658 | $45 |
| Trospium Chloride | 36 | $4,322 | $120 |
| Cefaclor | 47 | $3,672 | $78 |
| Bicalutamide | 73 | $3,375 | $46 |
| Dutasteride | 43 | $3,289 | $76 |
| Oxybutynin Chloride | 126 | $2,799 | $22 |
| Amoxicillin-Clavulanate Potass | 268 | $1,775 | $7 |
| Estradiol | 16 | $1,685 | $105 |
| Nitrofurantoin Mono-Macro | 36 | $1,678 | $47 |
| Solifenacin | 11 | $1,453 | $132 |
| Ciprofloxacin | 414 | $1,390 | $3 |
| Doxycycline Hyclate | 92 | $1,374 | $15 |
| Bethanechol Chloride | 18 | $888 | $49 |
| Testosterone Cypionate | 17 | $883 | $52 |
| Doxazosin Mesylate | 18 | $735 | $41 |
| Sildenafil Citrate | 49 | $650 | $13 |
| Alfuzosin Hcl Er | 16 | $476 | $30 |
| Cefdinir | 26 | $440 | $17 |
| Terazosin | 19 | $353 | $19 |
| Gabapentin | 16 | $323 | $20 |
| Ibuprofen | 45 | $157 | $3 |
| Sulfamethoxazole-Trimethoprim | 54 | $147 | $3 |
| Naproxen | 23 | $122 | $5 |
| Levofloxacin | 23 | $120 | $5 |
| Tramadol | 20 | $79 | $4 |
2021: 34 drugs
| Lupron Depot | 44 | $415,072 | $9,433 |
| Xtandi | 33 | $414,522 | $12,561 |
| Myrbetriq | 342 | $225,195 | $658 |
| Elmiron | 84 | $99,708 | $1,187 |
| Tamsulosin | 1,265 | $31,302 | $25 |
| Toviaz | 24 | $16,474 | $686 |
| Finasteride | 565 | $13,137 | $23 |
| Oxybutynin Chloride Er | 236 | $10,210 | $43 |
| Bicalutamide | 73 | $3,908 | $54 |
| Dutasteride | 56 | $3,906 | $70 |
| Solifenacin | 13 | $3,234 | $249 |
| Oxybutynin Chloride | 139 | $3,140 | $23 |
| Estradiol | 18 | $2,203 | $122 |
| Nitrofurantoin Mono-Macro | 57 | $1,785 | $31 |
| Testosterone | 12 | $1,664 | $139 |
| Silodosin | 14 | $1,467 | $105 |
| Amoxicillin-Clavulanate Potass | 241 | $1,376 | $6 |
| Doxycycline Hyclate | 71 | $1,268 | $18 |
| Trospium Chloride | 21 | $1,168 | $56 |
| Ciprofloxacin | 339 | $1,002 | $3 |
| Bethanechol Chloride | 17 | $897 | $53 |
| Doxazosin Mesylate | 23 | $872 | $38 |
| Cefaclor | 11 | $812 | $74 |
| Cephalexin | 31 | $603 | $19 |
| Alfuzosin Hcl Er | 17 | $525 | $31 |
| Sildenafil Citrate | 38 | $490 | $13 |
| Tramadol | 66 | $294 | $4 |
| Sulfamethoxazole-Trimethoprim | 76 | $291 | $4 |
| Terazosin | 15 | $260 | $17 |
| Diclofenac | 11 | $163 | $15 |
| Gabapentin | 12 | $134 | $11 |
| Ibuprofen | 31 | $122 | $4 |
| Naproxen | 21 | $92 | $4 |
| Levofloxacin | 14 | $65 | $5 |
2020: 38 drugs
| Myrbetriq | 494 | $248,547 | $503 |
| Lupron Depot | 22 | $198,588 | $9,027 |
| Xtandi | 12 | $151,184 | $12,599 |
| Elmiron | 101 | $115,317 | $1,142 |
| Tamsulosin | 1,359 | $27,858 | $20 |
| Toviaz | 37 | $16,245 | $439 |
| Finasteride | 618 | $12,224 | $20 |
| Oxybutynin Chloride Er | 218 | $8,864 | $41 |
| Testosterone | 20 | $7,053 | $353 |
| Cialis | 14 | $5,269 | $376 |
| Dutasteride | 76 | $5,186 | $68 |
| Oxybutynin Chloride | 214 | $4,032 | $19 |
| Nitrofurantoin Mono-Macro | 74 | $3,333 | $45 |
| Estradiol | 17 | $3,277 | $193 |
| Trospium Chloride | 15 | $2,791 | $186 |
| Bicalutamide | 48 | $2,252 | $47 |
| Silodosin | 20 | $2,044 | $102 |
| Ciprofloxacin | 488 | $1,815 | $4 |
| Cefaclor | 31 | $1,615 | $52 |
| Solifenacin | 21 | $1,299 | $62 |
| Bethanechol Chloride | 17 | $1,137 | $67 |
| Amoxicillin-Clavulanate Potass | 125 | $1,113 | $9 |
| Doxazosin Mesylate | 30 | $1,039 | $35 |
| Testosterone Cypionate | 13 | $644 | $50 |
| Doxycycline Hyclate | 33 | $583 | $18 |
| Alfuzosin Hcl Er | 25 | $404 | $16 |
| Sildenafil Citrate | 34 | $376 | $11 |
| Terazosin | 19 | $322 | $17 |
| Sulfamethoxazole-Trimethoprim | 73 | $280 | $4 |
| Cephalexin | 43 | $272 | $6 |
| Diclofenac | 13 | $207 | $16 |
| Levofloxacin | 27 | $186 | $7 |
| Tramadol | 64 | $185 | $3 |
| Ibuprofen | 27 | $128 | $5 |
| Naproxen | 28 | $117 | $4 |
| Diclofenac | 18 | $115 | $6 |
| Gabapentin | 13 | $110 | $8 |
| Hydroxyzine | 16 | $90 | $6 |
2019: 38 drugs
| Lupron Depot | 25 | $239,139 | $9,566 |
| Myrbetriq | 419 | $185,021 | $442 |
| Xtandi | 13 | $156,276 | $12,021 |
| Elmiron | 121 | $136,804 | $1,131 |
| Vesicare | 68 | $32,216 | $474 |
| Tamsulosin | 1,548 | $25,244 | $16 |
| Finasteride | 733 | $11,679 | $16 |
| Solifenacin | 52 | $10,499 | $202 |
| Premarin | 25 | $10,292 | $412 |
| Oxybutynin Chloride Er | 213 | $7,320 | $34 |
| Toviaz | 18 | $7,286 | $405 |
| Cialis | 17 | $7,082 | $417 |
| Testosterone | 17 | $5,389 | $317 |
| Dutasteride | 77 | $4,930 | $64 |
| Oxybutynin Chloride | 299 | $3,400 | $11 |
| Estradiol | 18 | $3,242 | $180 |
| Tolterodine Tartrate Er | 11 | $2,534 | $230 |
| Bicalutamide | 90 | $2,332 | $26 |
| Nitrofurantoin Mono-Macro | 71 | $2,322 | $33 |
| Ciprofloxacin | 336 | $1,829 | $5 |
| Silodosin | 13 | $1,388 | $107 |
| Amoxicillin-Clavulanate Potass | 99 | $1,225 | $12 |
| Bethanechol Chloride | 23 | $1,088 | $47 |
| Doxycycline Hyclate | 32 | $971 | $30 |
| Alfuzosin Hcl Er | 44 | $924 | $21 |
| Testosterone Cypionate | 13 | $748 | $58 |
| Doxazosin Mesylate | 24 | $628 | $26 |
| Gabapentin | 26 | $495 | $19 |
| Terazosin | 21 | $435 | $21 |
| Cephalexin | 51 | $340 | $7 |
| Sulfamethoxazole-Trimethoprim | 53 | $255 | $5 |
| Naproxen | 47 | $243 | $5 |
| Ibuprofen | 31 | $201 | $6 |
| Levofloxacin | 16 | $178 | $11 |
| Alendronate | 12 | $111 | $9 |
| Tramadol | 34 | $111 | $3 |
| Diclofenac | 11 | $60 | $5 |
| Ibu | 15 | $57 | $4 |
2018: 32 drugs
| Lupron Depot | 30 | $258,989 | $8,633 |
| Xtandi | 11 | $124,867 | $11,352 |
| Myrbetriq | 245 | $101,560 | $415 |
| Vesicare | 206 | $100,405 | $487 |
| Elmiron | 75 | $68,410 | $912 |
| Tamsulosin | 1,170 | $20,538 | $18 |
| Cialis | 20 | $8,511 | $426 |
| Toviaz | 25 | $8,501 | $340 |
| Premarin | 18 | $6,554 | $364 |
| Finasteride | 437 | $5,567 | $13 |
| Oxybutynin Chloride Er | 146 | $5,404 | $37 |
| Oxybutynin Chloride | 240 | $3,648 | $15 |
| Nitrofurantoin Mono-Macro | 64 | $2,305 | $36 |
| Bicalutamide | 93 | $1,925 | $21 |
| Ciprofloxacin | 249 | $1,830 | $7 |
| Doxycycline Hyclate | 26 | $1,579 | $61 |
| Dutasteride | 37 | $1,554 | $42 |
| Amoxicillin-Clavulanate Potass | 58 | $791 | $14 |
| Bethanechol Chloride | 18 | $718 | $40 |
| Alfuzosin Hcl Er | 34 | $655 | $19 |
| Sulfamethoxazole-Trimethoprim | 84 | $605 | $7 |
| Cephalexin | 71 | $576 | $8 |
| Doxazosin Mesylate | 16 | $477 | $30 |
| Naproxen | 66 | $384 | $6 |
| Testosterone Cypionate | 11 | $362 | $33 |
| Gabapentin | 29 | $332 | $11 |
| Hydrocodone-Acetaminophen | 44 | $329 | $7 |
| Levofloxacin | 32 | $317 | $10 |
| Tramadol | 37 | $120 | $3 |
| Alendronate | 12 | $120 | $10 |
| Terazosin | 15 | $118 | $8 |
| Sertraline | 18 | $79 | $4 |
2017: 31 drugs
| Lupron Depot | 28 | $223,948 | $7,998 |
| Xtandi | 18 | $184,651 | $10,258 |
| Vesicare | 261 | $98,826 | $379 |
| Elmiron | 66 | $53,165 | $806 |
| Myrbetriq | 98 | $35,618 | $363 |
| Tamsulosin | 1,054 | $18,573 | $18 |
| Finasteride | 390 | $4,092 | $10 |
| Bicalutamide | 120 | $3,848 | $32 |
| Premarin | 11 | $3,829 | $348 |
| Estrace | 12 | $3,572 | $298 |
| Dutasteride-Tamsulosin | 22 | $2,777 | $126 |
| Oxybutynin Chloride | 151 | $2,552 | $17 |
| Tolterodine Tartrate Er | 14 | $2,460 | $176 |
| Trospium Chloride | 13 | $2,012 | $155 |
| Oxybutynin Chloride Er | 42 | $1,612 | $38 |
| Nitrofurantoin Mono-Macro | 41 | $1,565 | $38 |
| Doxycycline Hyclate | 24 | $1,524 | $64 |
| Dutasteride | 41 | $979 | $24 |
| Amoxicillin-Clavulanate Potass | 51 | $869 | $17 |
| Ciprofloxacin | 130 | $839 | $6 |
| Cephalexin | 94 | $738 | $8 |
| Alfuzosin Hcl Er | 43 | $603 | $14 |
| Doxazosin Mesylate | 28 | $482 | $17 |
| Sulfamethoxazole-Trimethoprim | 83 | $408 | $5 |
| Hydrocodone-Acetaminophen | 48 | $377 | $8 |
| Naproxen | 40 | $209 | $5 |
| Tramadol | 42 | $134 | $3 |
| Gabapentin | 17 | $128 | $8 |
| Terazosin | 13 | $123 | $9 |
| Levofloxacin | 18 | $86 | $5 |
| Alendronate | 12 | $65 | $5 |
2016: 33 drugs
| Lupron Depot | 22 | $157,466 | $7,158 |
| Vesicare | 361 | $110,898 | $307 |
| Elmiron | 116 | $76,984 | $664 |
| Tamsulosin | 1,413 | $29,644 | $21 |
| Myrbetriq | 62 | $19,996 | $323 |
| Rapaflo | 53 | $11,897 | $224 |
| Toviaz | 31 | $8,085 | $261 |
| Avodart | 44 | $7,673 | $174 |
| Finasteride | 586 | $5,080 | $9 |
| Cialis | 19 | $4,849 | $255 |
| Nitrofurantoin Mono-Macro | 103 | $4,162 | $40 |
| Premarin | 12 | $3,638 | $303 |
| Dutasteride-Tamsulosin | 26 | $3,333 | $128 |
| Tolterodine Tartrate Er | 16 | $3,175 | $198 |
| Doxycycline Hyclate | 41 | $2,992 | $73 |
| Estrace | 11 | $2,915 | $265 |
| Bicalutamide | 148 | $2,599 | $18 |
| Trospium Chloride Er | 13 | $1,977 | $152 |
| Oxybutynin Chloride Er | 62 | $1,942 | $31 |
| Dutasteride | 61 | $1,860 | $30 |
| Oxybutynin Chloride | 123 | $1,773 | $14 |
| Ciprofloxacin | 196 | $1,248 | $6 |
| Doxazosin Mesylate | 44 | $867 | $20 |
| Cephalexin | 107 | $763 | $7 |
| Hydrocodone-Acetaminophen | 79 | $763 | $10 |
| Amoxicillin-Clavulanate Potass | 50 | $721 | $14 |
| Sulfamethoxazole-Trimethoprim | 129 | $683 | $5 |
| Bethanechol Chloride | 18 | $495 | $28 |
| Alfuzosin Hcl Er | 33 | $402 | $12 |
| Naproxen | 75 | $302 | $4 |
| Tramadol | 45 | $184 | $4 |
| Levofloxacin | 27 | $144 | $5 |
| Gabapentin | 18 | $117 | $6 |
2015: 31 drugs
| Lupron Depot | 17 | $114,260 | $6,721 |
| Vesicare | 339 | $87,593 | $258 |
| Elmiron | 129 | $87,117 | $675 |
| Tamsulosin | 1,448 | $57,134 | $39 |
| Rapaflo | 170 | $34,651 | $204 |
| Avodart | 129 | $21,184 | $164 |
| Toviaz | 40 | $10,098 | $252 |
| Premarin | 36 | $9,672 | $269 |
| Finasteride | 661 | $8,220 | $12 |
| Myrbetriq | 24 | $7,343 | $306 |
| Cialis | 28 | $5,866 | $210 |
| Bicalutamide | 191 | $4,647 | $24 |
| Jalyn | 24 | $3,831 | $160 |
| Oxybutynin Chloride Er | 74 | $3,577 | $48 |
| Nitrofurantoin Mono-Macro | 84 | $3,499 | $42 |
| Tolterodine Tartrate Er | 18 | $3,259 | $181 |
| Doxycycline Hyclate | 31 | $2,902 | $94 |
| Oxybutynin Chloride | 132 | $1,907 | $14 |
| Doxazosin Mesylate | 62 | $1,347 | $22 |
| Hydrocodone-Acetaminophen | 116 | $988 | $9 |
| Sulfamethoxazole-Trimethoprim | 181 | $962 | $5 |
| Cephalexin | 130 | $932 | $7 |
| Ciprofloxacin | 118 | $886 | $8 |
| Phenazopyridine | 21 | $729 | $35 |
| Alfuzosin Hcl Er | 45 | $606 | $13 |
| Amoxicillin-Clavulanate Potass | 46 | $601 | $13 |
| Bethanechol Chloride | 13 | $394 | $30 |
| Naproxen | 86 | $381 | $4 |
| Levofloxacin | 31 | $381 | $12 |
| Tramadol | 54 | $204 | $4 |
| Imipramine | 11 | $134 | $12 |
2014: 31 drugs
| Lupron Depot | 22 | $124,921 | $5,678 |
| Elmiron | 189 | $118,358 | $626 |
| Vesicare | 493 | $112,751 | $229 |
| Tamsulosin | 1,370 | $33,576 | $25 |
| Rapaflo | 184 | $30,361 | $165 |
| Avodart | 164 | $24,495 | $149 |
| Myrbetriq | 48 | $14,205 | $296 |
| Premarin | 44 | $9,500 | $216 |
| Toviaz | 40 | $7,891 | $197 |
| Finasteride | 527 | $7,727 | $15 |
| Bicalutamide | 196 | $7,579 | $39 |
| Nitrofurantoin Mono-Macro | 137 | $6,860 | $50 |
| Oxybutynin Chloride Er | 121 | $6,424 | $53 |
| Doxycycline Hyclate | 39 | $4,387 | $112 |
| Tolterodine Tartrate Er | 24 | $4,290 | $179 |
| Jalyn | 29 | $4,071 | $140 |
| Cialis | 20 | $3,835 | $192 |
| Oxybutynin Chloride | 221 | $3,677 | $17 |
| Alfuzosin Hcl Er | 59 | $2,087 | $35 |
| Trospium Chloride Er | 11 | $1,792 | $163 |
| Sulfamethoxazole-Trimethoprim | 233 | $1,519 | $7 |
| Doxazosin Mesylate | 53 | $1,188 | $22 |
| Ciprofloxacin | 149 | $1,157 | $8 |
| Hydrocodone-Acetaminophen | 108 | $955 | $9 |
| Cephalexin | 96 | $916 | $10 |
| Naproxen | 109 | $638 | $6 |
| Amox Tr-Potassium Clavulanate | 25 | $459 | $18 |
| Phenazopyridine | 25 | $441 | $18 |
| Imipramine | 27 | $360 | $13 |
| Levofloxacin | 35 | $307 | $9 |
| Tramadol | 40 | $176 | $4 |
2013: 36 drugs
| Vesicare | 566 | $118,118 | $209 |
| Elmiron | 202 | $106,194 | $526 |
| Lupron Depot | 15 | $76,501 | $5,100 |
| Avodart | 238 | $32,530 | $137 |
| Rapaflo | 161 | $23,500 | $146 |
| Tamsulosin | 1,216 | $20,894 | $17 |
| Androgel | 39 | $14,748 | $378 |
| Myrbetriq | 36 | $9,461 | $263 |
| Detrol La | 41 | $9,311 | $227 |
| Bicalutamide | 150 | $8,542 | $57 |
| Nitrofurantoin Mono-Macro | 124 | $7,122 | $57 |
| Finasteride | 351 | $6,888 | $20 |
| Doxycycline Hyclate | 53 | $6,661 | $126 |
| Oxybutynin Chloride Er | 134 | $6,145 | $46 |
| Jalyn | 43 | $5,655 | $132 |
| Alfuzosin | 73 | $3,144 | $43 |
| Premarin | 14 | $2,532 | $181 |
| Oxybutynin Chloride | 224 | $2,434 | $11 |
| Viagra | 17 | $2,169 | $128 |
| Toviaz | 12 | $2,059 | $172 |
| Sulfamethoxazole-Trimethoprim | 243 | $1,934 | $8 |
| Cefaclor | 22 | $1,692 | $77 |
| Ciprofloxacin | 212 | $1,429 | $7 |
| Doxazosin Mesylate | 93 | $1,001 | $11 |
| Naproxen | 143 | $926 | $6 |
| Cephalexin | 80 | $878 | $11 |
| Hydrocodone-Acetaminophen | 82 | $838 | $10 |
| Imipramine | 25 | $515 | $21 |
| Levofloxacin | 39 | $406 | $10 |
| Terazosin | 65 | $377 | $6 |
| Bethanechol Chloride | 12 | $356 | $30 |
| Phenazopyridine | 54 | $349 | $6 |
| Clotrimazole | 11 | $225 | $20 |
| Amox Tr-Potassium Clavulanate | 11 | $224 | $20 |
| Tramadol | 43 | $196 | $5 |
| Sertraline | 15 | $117 | $8 |
Money from drug and device companies
$1,180 in 2025
| 2025 | 13 | 39 | None | $1,180 |
| 2024 | 11 | 47 | None | $1,257 |
| 2023 | 13 | 42 | None | $1,297 |
| 2022 | 16 | 34 | None | $1,542 |
| 2021 | 10 | 43 | None | $1,083 |
| 2020 | 5 | 25 | None | $12,724 |
| 2019 | 12 | 62 | None | $8,180 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
SN Holdings, LLC
$75,179
Held by this doctor · 2024, 2023, 2022, 2021 · Common Stock
UroGPO LLC
$84,937
Held by this doctor · 2020, 2019 · Common Stock
Published ownership or investment in a drug or device company. This is not proof that care is biased.
A payment is not proof that care is biased.
| Pfizer | Xtandi | $308 | 10 payments
|
| Sumitomo Pharma America | Gemtesa | $178 | 7 payments
|
| Calyxo | Cvac Aspiration System | $166 | 2 payments
|
| Teleflex | Urolift | $123 | 5 payments
|
| Accord Healthcare | Camcevi | $71 | 3 payments
|
| Coloplast | Titan | $67 | 3 payments
|
See all 39 published payments
| Pfizer | Meals · 2025-11-21 | Xtandi | $27 |
| Calyxo | Meals · 2025-11-19 | Cvac Aspiration System | $20 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-13 | Nubeqa | $30 |
| Teleflex | Meals · 2025-11-06 | Urolift | $27 |
| Accord Healthcare | Meals · 2025-11-06 | Camcevi | $24 |
| Pfizer | Meals · 2025-10-25 | Xtandi | $4 |
| Pfizer | Meals · 2025-08-29 | Xtandi | $16 |
| Procept Biorobotics | Meals · 2025-08-28 | Aquabeam Robotic System | $31 |
| Teleflex | Meals · 2025-08-26 | Urolift | $29 |
| Novartis Pharmaceuticals | Meals · 2025-08-18 | Pluvicto | $32 |
| Pfizer | Meals · 2025-08-08 | Xtandi | $26 |
| Boston Scientific | Meals · 2025-07-31 | Overstitch Endoscopic Suturing System | $50 |
| Sumitomo Pharma America | Meals · 2025-07-28 | Orgovyx | $28 |
| Pfizer | Meals · 2025-07-11 | Xtandi | $25 |
| Coloplast | Meals · 2025-06-12 | Coloplast Tfl Drive | $20 |
| Pfizer | Meals · 2025-06-02 | Xtandi | $24 |
| Sumitomo Pharma America | Meals · 2025-05-29 | Gemtesa | $27 |
| Teleflex | Meals · 2025-05-29 | Barrigel | $18 |
| Sumitomo Pharma America | Meals · 2025-05-28 | Orgovyx | $23 |
| Janssen Biotech | Meals · 2025-05-22 | Erleada | $30 |
| Pfizer | Meals · 2025-05-16 | Xtandi | $125 |
| Coloplast | Meals · 2025-05-14 | Titan | $27 |
| Progenics Pharmaceuticals | Meals · 2025-05-01 | Pylarify | $23 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-04-30 | Nubeqa | $23 |
| Calyxo | Meals · 2025-04-23 | Cvac Aspiration System | $146 |
| Accord Healthcare | Meals · 2025-04-10 | Camcevi | $22 |
| Sumitomo Pharma America | Meals · 2025-04-09 | Gemtesa | $10 |
| Pfizer | Meals · 2025-04-07 | Xtandi | $13 |
| Myriad Genetic Laboratories | Meals · 2025-03-27 | Prolaris | $25 |
| Pfizer | Meals · 2025-03-14 | Xtandi | $19 |
| Sumitomo Pharma America | Meals · 2025-03-12 | Orgovyx | $30 |
| Sumitomo Pharma America | Meals · 2025-03-10 | Gemtesa | $31 |
| Janssen Biotech | Meals · 2025-03-06 | Erleada | $21 |
| Coloplast | Meals · 2025-02-26 | Saffron | $21 |
| Pfizer | Meals · 2025-02-20 | Xtandi | $28 |
| Accord Healthcare | Meals · 2025-02-20 | Camcevi | $24 |
| Teleflex | Meals · 2025-02-17 | Barrigel | $26 |
| Sumitomo Pharma America | Meals · 2025-01-28 | Gemtesa | $30 |
| Teleflex | Meals · 2025-01-03 | Solesta | $22 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,257
| Pfizer | Xtandi | $288 | 15 payments
|
| Sumitomo Pharma America | Gemtesa | $255 | 12 payments
|
| Janssen Biotech | Erleada | $219 | 6 payments
|
| PROCEPT BioRobotics | Aquabeam System | $139 | 1 payment
|
| ConvaTec | Gentlecath | $108 | 3 payments
|
| Teleflex | Urolift | $82 | 3 payments
|
| Myriad Genetic Laboratories | Prolaris | $71 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $30 | 1 payment
|
| Astellas Pharma US | Xtandi | $26 | 1 payment
|
| Accord Healthcare | Camcevi | $24 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $15 | 1 payment
|
2023: $1,297
| Myriad Genetic Laboratories | Prolaris | $339 | 6 payments
|
| Sumitomo Pharma America | Gemtesa | $213 | 8 payments
|
| Teleflex | Urolift | $175 | 4 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $111 | 4 payments
|
| Janssen Biotech | Erleada | $108 | 5 payments
|
| Pfizer | Xtandi | $81 | 3 payments
|
| ConvaTec | Gentlecath | $71 | 3 payments
|
| Coloplast | Speedicath | $71 | 3 payments
|
| Accord Healthcare | Camcevi | $41 | 2 payments
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $36 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $22 | 1 payment
|
| Supernus Pharmaceuticals | Tlando | $19 | 1 payment
|
| Rigicon | Rigi10 Malleable Penile Prosthesis | $11 | 1 payment
|
2022: $1,542
| SN Holdings | None | $868 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $99 | 4 payments
|
| Urovant Sciences | Gemtesa | $80 | 4 payments
|
| Myovant Sciences | Orgovyx | $76 | 3 payments
|
| Coloplast | Titan | $64 | 4 payments
|
| Myriad Genetic Laboratories | Prolaris | $58 | 3 payments
|
| Teleflex | Urolift | $53 | 2 payments
|
| Axonics | Bulkamid | $46 | 2 payments
|
| Astellas Pharma US | Xtandi | $43 | 2 payments
|
| Antares Pharma | Nocdurna | $31 | 2 payments
|
| Abbvie | Lupron Depot | $28 | 1 payment
|
| Pfizer | Xtandi | $26 | 1 payment
|
| UroGen Pharma | Jelmyto | $23 | 1 payment
|
| ConvaTec | Gentlecath | $20 | 1 payment
|
| Boston Scientific | Lynx System | $15 | 1 payment
|
| Accord Healthcare | Camcevi | $12 | 1 payment
|
2021: $1,083
| Coloplast | Titan | $268 | 14 payments
|
| Dornier MedTech America | Consumables & Accessories | $258 | 1 payment
|
| Astellas Pharma US | Xtandi | $178 | 10 payments
|
| Myriad Genetic Laboratories | Bracanalysis Cdx | $95 | 5 payments
|
| Janssen Biotech | Erleada | $92 | 4 payments
|
| Teleflex | Urolift System | $70 | 3 payments
|
| Urovant Sciences | Gemtesa | $40 | 2 payments
|
| Antares Pharma | Xyosted | $36 | 2 payments
|
| Myovant Sciences | Orgovyx | $26 | 1 payment
|
| Pfizer | Xtandi | $20 | 1 payment
|
2020: $12,724
| Coloplast | Titan | $12,120 | 8 payments
|
| Astellas Pharma US | Xtandi | $337 | 9 payments
|
| Medtronic USA | None | $121 | 1 payment
|
| NeoTract | Urolift | $120 | 5 payments
|
| C. R. Bard Inc. & Subsidiaries | Inlay | $27 | 2 payments
|
2019: $8,180
| Coloplast | Titan | $7,323 | 14 payments
|
| Pfizer | Xtandi | $222 | 14 payments
|
| Astellas Pharma US | Xtandi | $219 | 12 payments
|
| NeoTract | Urolift | $94 | 4 payments
|
| Janssen Biotech | Erleada | $91 | 6 payments
|
| Boston Scientific | General Bph | $71 | 4 payments
|
| Dendreon Pharmaceuticals | Provenge | $45 | 2 payments
|
| Amgen | Prolia | $33 | 1 payment
|
| Medtronic USA | Interstim | $33 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $22 | 1 payment
|
| Endo Pharmaceuticals | Xiaflex | $16 | 1 payment
|
| Ferring Pharmaceuticals | Nocdurna | $11 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AstraZeneca Pharmaceuticals LP · A Randomised,Double Blind,Placebo Controlled,Adaptive,Population Enrichment Phase III Study of Azd5305 in Men With Metastatic Castration Sensitive Prostate Cancer Receiving Physician Is Choice New Hormonal Agents · 2024 | Their institution | $22,322 |
| AstraZeneca Pharmaceuticals LP · A Randomized 2-Cohort Double-Blind Placebo-Controlled Phase III Study of Azd5305 in Combination With Physicians Choice New Hormonal Agents in Patients With Hrrm and Non-Hrrm Metastatic Castration-Sensitive Prostate Cancer Evopar-Prostate01 · 2025 | Their institution | $7,945 |
Checkups this office reported
11 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 8%That's few of the people this applied to. | 49 |
| Benign Prostate Hyperplasia (BPH): Inappropriate Lab & Imaging Services for Patients with BPHAs Medicare defines this measure | 0% | 340 |
| Colon cancer screeningEligible adults who got a colon cancer test | 2%That's few of the people this applied to. | 1,558 |
| Hospital admissions or infectious complications within 30 days of prostate biopsyAs Medicare defines this measure | 0% | 65 |
| Medications listed in the chartVisits where the current medication list was documented | 96%That's most of the people this applied to. | 5,136 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 94%That's most of the people this applied to. | 1,140 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 76%That's most of the people this applied to. | 943 |
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 0%That's few of the people this applied to. Better on this measure. | 1,573 |
See the other 3 measures
| Stones: Urinalysis Performed Before Surgical Stone ProceduresAs Medicare defines this measure | 91% | 55 |
| Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and OlderAs Medicare defines this measure | 100% | 259 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 11%That's few of the people this applied to. | 2,561 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Did a security review of patient data
- Implementation of medication management practice improvements
- Improved the patient portal
- Reports cases to public health electronically
- Reports to a public-health or clinical registry
- Exempt from immunization registry reporting
- Exempt from support electronic referral loops by receiving and reconciling health information
- Exempt from support electronic referral loops by sending health information
Professional record
- NPI
- 1609834217
- Licence
- CA A40197California A40197: Current · expires 2028-08-31
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A401970
- Taxonomy
- Urology (208800000X)
- Mailing address
- Po Box 303, Surfside, CA, 90743
- NPI first listed
- 2006-05-03
- NPI last updated
- 2010-03-03
This is when the NPI record was last certified, not a medical board exam.